article thumbnail

FDA’s Revised Draft Guidance on Biological Product Promotion Provides Additional Recommendations/Clarifications

The FDA Law Blog

Promotional labeling is generally any labeling other than FDA-required labeling that is devised for the promotion of a product, as well as other functions, and can include printed, audio, or visual matter that describes the product. l)(1) (e.g.,

article thumbnail

FDA-Approved Labeling: Is Enough Enough?

The FDA Law Blog

Livornese — I saw the sign…and the answer is no—FDA-approved labeling apparently is not enough under state failure-to-warn laws, according to certain courts. Most OTC drugs, particularly drugs that have been around for a while, are primarily marketed pursuant to OTC monographs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

COVID At-Home Antigen Tests: If at First You Don’t Succeed Try, Try and Try Again

The FDA Law Blog

Ironically, a recent FDA safety communication points to a potential way out of this dilemma. In this safety communication, FDA advises the public as follows: If you test negative and have COVID-19 symptoms , you test again 48 hours later for a total of two tests.

article thumbnail

PRISYM 360 Achieves SAP® Certification as Integrated with Cloud Solutions from SAP

pharmaphorum

Wokingham, United Kingdom — 7 December 2020 — PRISYM ID, a leading provider of regulated content and label management solutions for the life sciences sector, announced today that PRISYM 360 version 1.10 PRISYM 360 and SAP technologies communicate through a web service using standard SAP components with no intermediate stages.

article thumbnail

Disrupted medical conferences: Lessons learnt

pharmaphorum

It currently appears highly unlikely that the majority of conferences will simply return to typical face-to-face only formats as they were before 2020. This article summarises the most important lessons learnt during 2020 – 2021. Lessons learnt 2020-2021. Part 2 will assess possible scenarios for 2022 and beyond.

Labelling 105
article thumbnail

Industry group says FDA botched COVID-19 convalescent plasma guidance

pharmaphorum

Bioindustry association MichBio says the FDA’s labelling requirements for COVID-19 convalescent plasma (CCP) – which were published alongside the emergency use authorisation – could lead to “hundreds, if not thousands, of in-date, ready to transfuse CCP units across the country being rendered unusable.”. The @CDCgov was muzzled months ago.

FDA 105
article thumbnail

FDA holds back from action over Xeljanz safety study

pharmaphorum

billion in the first nine months of 2020, up 10% overall and 23% in ex-US markets. After the ORAL Surveillance data emerged, analysts debated whether the FDA might take action either to remove Xeljanz from the market or – perhaps more likely – update its labelling to reflect the new data and leave prescribing decisions to doctor discretion.

FDA 58